4106.Tw

The company maintains a conservative capital structure with a debt-to-equity ratio of 0.1, indicating a low reliance on debt financing. Its liquidity position is characterized by a current ratio of 3.13, suggesting strong short-term liquidity. However, the company has negative net cash after subtracting total debt, which may raise concerns about its ability to meet short-term obligations without additional financing. The price-to-book ratio of 0.94 indicates that the company's market value is slightly below its book value, suggesting potential undervaluation or weak investor sentiment.

In terms of profitability, the company's return on equity (ROE) is 4.79%, and its return on assets (ROA) is 3.81%, both of which are below the industry median for medical equipment and supplies firms. The gross profit margin is 45.9%, which is in line with the industry average, but the operating margin of 6.3% is below the median, indicating inefficiencies in cost management or pricing power. The net profit margin of 5.0% is also below the industry median, suggesting that the company is underperforming in converting revenue into net profit.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to regional economic downturns or regulatory changes. The company's revenue concentration in a single segment also limits its ability to offset performance declines in one area with growth in another.

The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. The company's operating cash flow of 207.45 million TWD and free cash flow of 66.25 million TWD indicate that it is generating positive cash flow, but the amount is relatively small compared to its revenue. The company's capital expenditure of -52.77 million TWD suggests that it is not investing heavily in new projects or equipment, which may limit its long-term growth potential.

The company's risk profile is characterized by medium liquidity risk and low dilution risk. The company's liquidity risk is moderate due to its strong current ratio but is offset by its negative net cash position. The company's dilution risk is low, as there is no indication of recent or planned share issuances that could dilute existing shareholders. The company's valuation is supported by a price-to-earnings ratio of 19.54 and an enterprise value-to-EBITDA ratio of 16.74, which are in line with industry averages.

Recent financial filings and transcripts do not indicate any major events or strategic shifts that would significantly impact the company's operations or financial performance. The company's financial statements show consistent performance, with no material changes in revenue, expenses, or cash flow.